Baltimore, MD (PRWEB) September 06, 2016

SNBL CPC demonstrates commitment to their clients by offering state-of-the-art services.

Shin Nippon Biomedical Laboratories, Clinical Pharmacology Center, Inc. (SNBL CPC), a leading early phase clinical research organization, continues to provide the best quality early stage clinical development services to sponsors. As a certified iCardiac site, SNBL CPC demonstrates commitment to their clients by offering the best, state-of-the-art services.

In December 2015, the International Council for Harmonisation revised the guidance that defines and enables an alternative path to the conduct of a Thorough QT (TQT) study. The new revision emerged following a prospective validation study in 2014 that was sponsored by iCardiac Technologies, Inc., utilizing iCardiac’s unique Early Precision QT methodology as well as its project management and analysis personnel. Sponsors working with an experienced iCardiac site using Early Precision QT, like SNBL, can potentially save millions in TQT study costs by obtaining critical information about their compounds earlier in development.

SNBL chose to become certified to conduct trials using iCardiac Early Precision QT to bring value to sponsors in countless ways. The patented iCardiac process was created after 30 years of research and allows sponsors ~10x more data than conventional measuring processes. Sponsors using this methodology can look forward to not only more data, which results in significantly less measurement variability, but also data which is less affected by signal noise and heart rate effects.

Click here to read the rest of the story on PRWeb